Literature DB >> 24019037

Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer.

T Xu1, X Liu, L Han, H Shen, L Liu, Y Shu.   

Abstract

PURPOSE: Emerging evidences indicate that dysregulated microRNAs are implicated in cancer tumorigenesis and progression. MicroRNA-9 (miR-9) has various expression patterns in diverse human cancers. However, its clinical significance in human non-small cell lung cancer has not yet been elucidated. In the present study, we detected the expression of miR-9 in non-small cell lung cancer and adjacent noncancerous tissues and explored its relationships with clinicopathological characteristics and prognosis.
METHODS: Expression levels of miR-9 in 116 pairs of non-small cell lung cancer and adjacent normal tissues were detected by real-time quantitative RT-PCR assay. To determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis.
RESULTS: MiR-9 expression in non-small cell lung cancer tissues was significantly higher than that in adjacent normal tissues (p = 0.001), and its up-regulation was significantly correlated to advanced tumor-node-metastasis (TNM) stage (p < 0.001), tumor size (p = 0.013), and lymph node metastasis (p = 0.001). Furthermore, Kaplan-Meier analysis demonstrated that high miR-9 expression clearly predicted poorer PFS (p < 0.001) and OS (p < 0.001). In the multivariate analysis, increased miR-9 expression was an independent prognostic factor for both PFS (p = 0.002) and OS (p = 0.013).
CONCLUSIONS: MiR-9 was up-regulated in non-small cell lung cancer tissues and correlated with adverse clinical features and unfavorable survival, indicating that miR-9 might be involved in non-small lung cancer progression and could serve as a promising biomarker for further risk stratification in the treatment of this cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24019037     DOI: 10.1007/s12094-013-1106-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  30 in total

Review 1.  Screening for lung cancer.

Authors:  E F Patz; P C Goodman; G Bepler
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

3.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

Authors:  Harubumi Kato; Yukito Ichinose; Morio Ohta; Enjo Hata; Noriaki Tsubota; Hirohito Tada; Yoh Watanabe; Hiromi Wada; Masahiro Tsuboi; Nobuyuki Hamajima; Mitsuo Ohta
Journal:  N Engl J Med       Date:  2004-04-22       Impact factor: 91.245

4.  Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma.

Authors:  M A T Hildebrandt; J Gu; J Lin; Y Ye; W Tan; P Tamboli; C G Wood; X Wu
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

5.  Reduced expression of E-cadherin in human non-small cell lung carcinoma.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 8.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

9.  Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer.

Authors:  Kengo Shigehara; Shigeki Yokomuro; Osamu Ishibashi; Yoshiaki Mizuguchi; Yasuo Arima; Yutaka Kawahigashi; Tomohiro Kanda; Ichiro Akagi; Takashi Tajiri; Hiroshi Yoshida; Toshihiro Takizawa; Eiji Uchida
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  35 in total

1.  MicroRNA-9 as a novel prognostic biomarker in human laryngeal squamous cell carcinoma.

Authors:  Shuo Wu; Shenshan Jia; Ping Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.

Authors:  Haifeng Wang; Wei Zhang; Yigang Zuo; Mingxia Ding; Changxing Ke; Ruping Yan; Hui Zhan; Jingyu Liu; Jiansong Wang
Journal:  Tumour Biol       Date:  2015-07-07

3.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

4.  Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study.

Authors:  Monika Migdalska-Sęk; Katarzyna Góralska; Sławomir Jabłoński; Jacek Kordiak; Ewa Nawrot; Justyna M Kiszałkiewicz; Dorota Pastuszak-Lewandoska; Kamila Baran; Michał Stuss; Ewa Brzeziańska-Lasota
Journal:  Mol Biol Rep       Date:  2019-11-09       Impact factor: 2.316

5.  Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer.

Authors:  Yajun Zhang; Hongbing Li; Jichang Han; Yijie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.

Authors:  Linbo Gao; David Cheng; Jie Yang; Renyi Wu; Wenji Li; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2018-02-09       Impact factor: 6.048

7.  The oncogenic and prognostic potential of eight microRNAs identified by a synergetic regulatory network approach in lung cancer.

Authors:  Ramkrishna Mitra; Zhongming Zhao
Journal:  Int J Comput Biol Drug Des       Date:  2014-12-25

Review 8.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

9.  Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.

Authors:  Yu Bai; Yong-Lian Wang; Wen-Jian Yao; Ling Guo; Hui-Fang Xi; Song-Yue Li; Bao-Sheng Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

10.  MicroRNA-9 is a ponderable index for the prognosis of human hepatocellular carcinoma.

Authors:  Jingchang Sun; Kunpeng Fang; Hang Shen; Yeben Qian
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.